EXCELYA
6.7.2020 08:02:10 CEST | Business Wire | Press release
Today, Excelya, a leading contract research organization (CRO) specializing in clinical research, announced that three European CROs joined Excelya Group: Zeincro based in Central-Eastern & Southern Europe, The Clinical Company based in the Netherlands and Belgium and Koehler eClinical based in Germany. Together, they will be known as Excelya Group. This alliance will allow Excelya to offer a one stop provider service model throughout Europe for its clients, whether they need full service, functional service providing or consulting services.
Zeincro is a leading contract research organization primarily operating in Central-Eastern & Southern Europe with particular expertise in clinical operations, safety and medical affairs. The Clinical Company is present in the Belgian and Dutch markets specializing in clinical operations. Koehler eClinical is a German specialty CRO with a focus on biostatistics and data solutions. Thanks to the unification with these three companies, Excelya Group is now a leading European full service CRO providing services in 24 European countries. Excelya Group now employs 800 people in six areas of expertise, with expected combined revenues of €70 million in 2020.
Francois Moisson, CEO at Excelya: “Our newly European scale and reach will allow us to provide a full suite of end-to-end clinical solutions for our clients where they need them. These investments in innovation and delivery capacity position us to rapidly continue our growth in the short and medium term.”
About Excelya Group
Excelya is an independent European contract research organization with over 800 employees, 17 offices and 12 legal entities spread throughout Europe. Excelya offers all cooperation models, from consulting to functional service providing to full-service. It provides these research services across multiple industries, including pharmaceutical, biotech, medical devices, cosmetics and nutrition. As a fully integrated CRO, Excelya undertakes the design and execution of Phase I clinical trials to post-marketing studies, safety, biometrics and market access projects. Excelya is committed to providing preeminent experts who work hand-in-hand with its clients to accelerate end-to-end drug development, leverage data science and reimagine patient care.
For more information, please visit excelya.com .
About Zeincro
Zeincro is a CRO created in 1999 headquartered in the United Kingdom that provides services to more than 20 countries in Central-Eastern & Southern Europe through eight offices. Zeincro provides a full range of services from Phases I to IV with a specialization in clinical operations and safety across most therapeutic areas. With almost 20 years of experience in more than 700 successful clinical studies completed, Zeincro has developed a thorough understanding of the communities and the regions in which it operates. This approach allows ZEINCRO to set new standards for successful clinical trials by delivering bespoke services that maximize patient recruitment and compliance.
For more information, please visit zeincro.com .
About Koehler eClinical GmbH
Koehler eClinical GmbH is a mid-size specialty CRO with more than 25 years of experience in providing value-added services for its customers. With its strong heritage in biostatistics, it covers all study phases as well as biostatistical and regulatory consulting, meta-analyses, data integration and standardizations. As a specialist in data-centric approaches, the company also operates its proprietary software VITESSA as a combined tool for electronic data capture and clinical trial management. Koehler eClinical GmbH provides full-service support for local and global trials with centralized project management and technology-enabled approaches. It covers the full spectrum of clinical projects, from early to late-phase, including NIS, observational and PASS.
For more information, please visit koehler-eclinical.com .
About The Clinical Company
Founded in 2002, The Clinical Company is based in Amstelveen, The Netherlands and Leuven, near Brussels, Belgium. The Clinical Company specializes in delivering clinical services in the Benelux to their (Bio)Pharmaceutical, Medical Device and CRO Clients. The Clinical Company is a full service CRO that provides services from Phases I to IV in all major therapeutic areas and conducts clinical trials in eight countries in Western Europe.
For more information, please visit theclinicalcompany.com .
Project Contributors :
- Excelya: François Moisson & Frédéric Paqueville (CEO & Co-Founders), Guillaume Steimer
-
Legal counsel:
- FieldFisher: Philippe Netto, Hélène Lefebvre, Antoine Gabizon (Fr), Mark Walker (UK), Louis Bouchez and Jan Schouten (NL), Florian Streiber (D), Louis-Francois du Castillon (Bel) ;
- De Pardieu Brocas Maffei: Philippe Rozec
- Financial Audit: Oderis, Aurélien Vion
- Financing: Banking pool (SG,LCL, CIC, HSBC), leading agent: Société Générale, Erkan Suer,
- Zeincro: Dr Gregory Sivolapenko,
- Koehler eClinical: Dr Manfred Koehler, Dr Antal Hajos, Michael Pfitzenmaier,
- The Clinical Company: Pim Van de Riet, Chris de Jong, Evert Cuppens, Stijn Valkering, Angélique Kleemans
-
Legal and financial advisors:
- Zeincro: CMS Cameron McKenna Nabarro Olswang LLP, John Finnemore
- The Clinical Company: CMS Derks Star Busmann N.V, Pieter van Duijvenvoorde, & Breezeholme Advisory Services, Pim van de Riet
- Koehler eClinical: Dr. Reinhard Hermes, & VALNES Corporate Finance GmbH, Michael Graser
View source version on businesswire.com: https://www.businesswire.com/news/home/20200705005014/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perma-Pipe Secures More Than $67 Million in New Orders in the Second Quarter of 202620.8.2026 19:02:00 CEST | Press release
Awards include significant Oil & Gas projects in MENA and Canada, as well as the Company's largest single leak detection project to date and continued growth at its new Ohio facility. Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH), a global leader in engineered piping and corrosion protection solutions, today announced that the Company secured more than $67 million in new orders during the second quarter of fiscal 2026, representing strong demand across its strategically important end-markets and geographies. The orders further strengthen Perma-Pipe's backlog and provide increased visibility into future revenue growth. The Company's backlog remains well diversified across geographies, customers and end-markets. The Company continued to see strong demand across its core Oil & Gas and infrastructure markets, while also securing important new business in emerging applications, including advanced leak detection and monitoring solutions. During the quarter, Perma-Pipe secured sizabl
Impartner Launches the First CPQ Built for Partners20.8.2026 15:00:00 CEST | Press release
New quote management capability brings configure, price, and quote (CPQ) into Impartner’s PRM platform, connecting product configuration, pricing, segmentation, and approvals. Impartner, the leading partner revenue orchestration platform, today announced the launch ofImpartner CPQ, giving partners a direct path to create and advance quotes within the Impartner PRM platform. The new capability enables faster movement from opportunity to submission while giving vendors control over the rules, products, pricing, and approvals that govern each transaction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260820479441/en/ Give partners a faster path from opportunity to quote with Impartner's CPQ. For many partnership programs, quoting remains a largely manual process. Partners often depend on vendor sales teams to prepare quotes because traditional CPQ systems are designed primarily for direct sellers or require additional licensin
Scientist.com Expands R&D Platform Capabilities with SciSure’s Integrated LabOps Inventory and Compliance Services20.8.2026 14:55:00 CEST | Press release
Strategic integration connects scientific procurement with lab operations, inventory, and EHS compliance Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, today announced an expansion of its platform capabilities through an integration with SciSure’s lab management and EHS compliance tools. The partnership gives biopharma organizations a more unified workflow connecting scientific procurement directly with laboratory operations. “By bringing SciSure’s inventory management, safety, and compliance capabilities into the Scientist.com ecosystem, we are closing the gap between sourcing reagents and safely managing them in the laboratory,” said Jon Zibell, VP of Global Alliances at SciSure. “Together, our platforms connect product information, safety checks, and inventory management, giving research, lab operations, and EHS teams greater visibility from purchase request through disposal.” The integration connects procurement, s
NETFORCE Accelerates Its U.S. Industrial Expansion as a New Intermediate-Force Market Takes Shape20.8.2026 14:23:00 CEST | Press release
Backed by two granted and active U.S. patents, a fully industrialized technology and commercial commitments spanning more than 50 countries, the French company is now seeking leading U.S. industrial and strategic partners to help shape the future of this emerging market. For the first time, major U.S. federal agencies are beginning to structure procurement around a new category of intermediate-force equipment, giving officers an additional option between verbal presence and higher levels of force. NETFORCE believes companies establishing themselves at this early stage will benefit from a significant first-mover advantage as this category expands nationwide. This is precisely the market NETFORCE anticipated years ago, having invested heavily in research, industrialization and international intellectual property well before the category attracted attention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260820951658/en/ COPYRI
Cox Capital To Expand Liquidity Solutions for Retail Investors in Private Markets20.8.2026 14:00:00 CEST | Press release
The liquidity solutions provider for alternative investments prepares to launch tender offers for interval funds in the coming months and affirms its ongoing program for non-traded BDCs. Cox Capital Partners, LP (“Cox Capital”), a provider of liquidity solutions for retail holders of illiquid alternative investments, today announced plans to expand its existing tender offer program for non‑traded business development companies (BDCs) into the rapidly growing interval fund market. The move affirms the company’s role as a provider of liquidity solutions across the private markets landscape for the wealth advisory channel. Over the past six years, Cox Capital has built a platform for sourcing and executing secondary liquidity transactions for retail investors in non‑traded BDCs and other illiquid vehicles, working with financial advisors and intermediaries across independent broker‑dealers, RIAs, and major wirehouses. Cox Capital today announced plans to expand that platform to interval f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
